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CASE DESCRIPTION
Over the last year, a 40-year-old man had complained
of weekly episodes of facial flushing, diaphoresis,
irritability,and diarrhea, which were triggered by emo-
tional stress or exercise. He also presented with chest
discomfort and had lost 6 kg. He had poorly controlled
essential hypertension that had lasted over the last six
years. On examination, his systolic blood pressure was
160 mm Hg, his diastolic blood pressure was 110 mm
Hg, his heart rate was 110 beats/min, and his body mass
index was 32 kg/m
2; he did not present with postural
hypotension. A small goiter without nodules and a slight
lid retraction were noted. He had no facial flushing
or hand tremor. During the che s td i s c o m f o r ti n v e s t i g a -
tion, the chest X-ray revealed an anterior mediastinal
enlargement.
A thoracic computed tomography (CT) scan revealed a
homogeneous mass with no adjacent structure invasion or
calcification at the topography of the thymus enlargement
(Figure 1A). Goiter was also detected but did not extend
to the intrathoracic compartment. A carcinoid syndrome
caused by a primary neuroendocrine tumor was sus-
pected.
The patients exams depicted normal values of urinary 5-
hydroxyindoleacetic acid (2.8 and 3.1 mg/24 h, normal
values-NV 2-6), urinary metanephrines (1.0 and 0.09 mcg/
mg creatinine, NV ,1.2), serum calcitonin (7.3 pg/mL, NV
,11.5), negative tumoral markers b-hCG and alpha-feto-
protein. Thyrotoxicosis was diagnosed from the following
fluoroimmunoassay measurements: total T3, 371 ng/dL
(NV 40–180 ng/dL); total T4, 20.9 mcg/dL (NV 4.5–
12 mcg/dL); free T4, 4.9 ng/dL (NV 0.7–1.5 ng/dL); and a
suppressed TSH,0.03 mUI/L (NV 0.4–4.5 mUI/L). Serum
antiperoxidase and antithyroglobulin antibodies measured
by fluoroimmunoassay were positive (859 and 72 U/mL,
NV,35 U/mL), with levels of TSH-receptor antibody
(TRab) of 49% (radioimmunometric assay NV,8%). Ultra-
sound thyroid imaging revealed a 43.2 g homogeneous
hypoechogenic goiter, which did not have nodules and was
limited to the neck.
Therefore, Graves’ disease was diagnosed, and a thymus
growth was then attributed to hyperplasia caused by
Graves’ disease.
Methimazol (20 mg/day) was initiated, and after four
months of treatment, symptoms had improved, and thyroid
hormones had normalized. Goiter and TRab values had
reduced. After six months of thyroid hormonal control, a
new CT revealed marked thymus shrinkage (Figure 1B).
After 24 months, the patient was in remission of
Graves disease, with negative TRab values and a normal
thoracic CT scan. Graves ophthalmopathy was never
presented.
DISCUSSION
We described a patient with systemic arterial hyperten-
sion and thoracic discomfort that presented an anterior
mediastinal mass and Graves disease. In adults, thymoma is
a common neoplasm of the anterior mediastinal compart-
ment and occurs between 40 and 60 years of age with a
slightly male predominance. Chest discomfort or pain is the
most common symptom.
However, our patient also presented episodic flushing,
diaphoresis, and diarrhea, which are common symptoms
for carcinoid syndrome. Together with the anterior
mediastinal enlargement, carcinoid syndrome that had
resulted from a neuroendocrine tumor was initially
suspected. Primary neuroendocrine tumors of the thymus
account for less than 5% of all anterior mediastinal
neoplasms. They are highly aggressive and more prevalent
in men during the fourth and fifth decades of life. The
symptoms are related to structure compression, distant
metastasis, or endocrinopathies, including carcinoid syn-
drome. A CT-scan usually shows a lobulated thymic mass
with heterogeneous enhancement and central areas of low
attenuation, before necrosis and hemorrhage, and even-
tually calcifications.
1 The presence of normal 24-hour
urinary vanillylmandelic acid and metanephrine levels
ruled out the possibility of neuroendocrine tumors. Normal
testing physical examination and undetectable alpha-
fetoprotein and beta human chorionic gonadotropin levels
also ruled out the possibility of nonseminomatous germ-
cell tumors.
1
Combining the hormonal thyroid abnormalities with the
thoracic CT characteristics, thymic hyperplasia due to
Graves disease was diagnosed. Thymic hyperplasia is
commonly associated with Graves’ disease, but it is not
emphasized in major endocrinology texts and must be
recognized by all physicians.
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2177There are two morphologic forms of thymus hyperplasia
associated with Graves’ disease: lymphoid hyperplasia and
true hyperplasia. The first is characterized by a thymus
medullary lymphoid-follicle formation that is not visualized
as an enlargement of the anterior mediastinal compart-
ment.
2 In contrast, the second form, true hyperplasia,
presents as an increase in thymic tissue. The mechanism
of both hyperplasias is not well established and could be
caused by excessive stimulation by the thyroid hormone or
TRab itself.
3,4
Few cases of detectable massive enlargements of the
thymus have been reported; most of these cases involved
thymectomy or biopsies to exclude the thymomas and
treatment of the remaining tissue with hyperthyroidism.
5,6
Because the association between Graves disease and thymic
hyperplasia is unclear, unnecessary approaches such as
sternotomy and transthoracic biopsy may be used.
7
In conclusion, thymic enlargement associated with
Graves’ disease, especially when a homogeneous mass
without a surrounding invasion, calcifications or a cystic
image is revealed from a thoracic CT-scan, allows for
judicious clinical and radiologic follow-up during the
hyperthyroidism treatment.
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Figure 1 - CT-scan images showing a thymus enlargement before (A) and after (B) treatment for hyperthyroidism due to Graves9
disease, with remarkable shrinkage of the thymus (arrows).
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